This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
2020 Business Update - Highlights

- **400K** patients treated
- **72% increase** in # of partnerships
- **$233M** in revenue

**Proved tech & business model**
- COVID-19 program with Eli Lilly brings bamlanivimab into clinical trials 90 days after initiation.
- Bamlanivimab authorized in 15 countries.

**Strengthened competitive advantage**
- Expanded technology stack with acquisitions OrthoMab™ and Trianni.
- Secured $126 million for CMC and GMP manufacturing capabilities.

**Positioned for growth with strong liquidity**
- $594 million in cash and $212 million in accounts receivable at year end.
Many life sciences companies have technologies that focus on one or a limited number of steps in the process. We believe we uniquely integrate proprietary technologies that address each of these steps.
2020 BUSINESS UPDATE. PARTNERSHIP BUSINESS MODEL

ACCELERATE DISCOVERY. SHARE IN THE SUCCESS.

| Partner | ABCELLERA
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIOTECH, PHARMA</td>
<td>mAb</td>
</tr>
<tr>
<td>target</td>
<td></td>
</tr>
</tbody>
</table>

Building a diversified portfolio of **milestones & royalties (primary value driver)**

### Discovery Research Fees
Near-term revenue from research payments (**capital efficient**)

### Milestones
Multimillion dollar potential clinical and commercial milestone payments

### Royalties
Majority of risk-adjusted value from royalty on commercial therapeutic sales

<table>
<thead>
<tr>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Approval</th>
<th>Commercial Sale</th>
</tr>
</thead>
</table>

**PARTNER**

**ABCELLERA**

**2020 BUSINESS UPDATE. PARTNERSHIP BUSINESS MODEL**

**ACCELERATE DISCOVERY. SHARE IN THE SUCCESS.**

**DISCOVERY RESEARCH FEES**
Near-term revenue from research payments (**capital efficient**)

**MILESTONES**
Multimillion dollar potential clinical and commercial milestone payments

**ROYALTIES**
Majority of risk-adjusted value from royalty on commercial therapeutic sales

**Copyright © AbCellera**

**5**
AI-POWERED PLATFORM BUILT ON REAL-WORLD DATA.

We believe our technology advantage comes from combining three things:

1. **Proprietary technologies** that can generate massive multidimensional antibody datasets
2. **Custom software** to aggregate, store, and maintain data
3. **Artificial intelligence** and powerful **computational tools** to extract actionable information from this data
DEMOCRATIZE THE INDUSTRY.

2020 BUSINESS UPDATE. TECHNOLOGY ADVANTAGE

MULTI-DIMENSIONAL DATA GENERATION

- millions of
- thousands of
- hundreds of thousands

- more CAPABILITIES
- more ACCESS
- more OPPORTUNITIES
- more PARTNERSHIPS
- more DATA + LEARNING
- smarter AI
- more BUSINESS GROWTH
- more FACILITIES + TECHNOLOGY ACQUISITIONS
- more TEAM KNOW-HOW

increasing TECHNOLOGY ADVANTAGE
UNLOCK NEW TARGETS. EMPOWER PARTNERS TO MOVE QUICKLY.
Together with its partners, AbCellera brought the first treatment developed specifically for COVID-19. Bamlnivimab is currently authorized in 15 countries, including the United States, Canada, Europe and the Middle East for the treatment of mild to moderate COVID-19 in high-risk patients.

From patient sample to human testing in 90 days

Sample received from one of the first US patients who recovered from COVID-19.

~5,800,000 cells screened in 3 days

24 leads identified in 23 days by evaluating 250,000 data points

One antibody in human clinical testing by Eli Lilly and Company
~400K PATIENTS TREATED WITH BAMLANIVIMAB

Bamlanivimab has been evaluated both alone and together with other antibodies in 5,000+ patients across multiple clinical trials. Bamlanivimab alone has been shown to:

- Reduce hospitalizations by 70% to 80% in patients recently diagnosed with mild to moderate COVID-19
- Prevent COVID-19 in nursing homes, reducing the risk of contracting COVID-19 by up to 80%
- Prevent COVID-19-related deaths
**COMBAT VARIANTS WITH BAMLANIVIMAB COMBINATIONS**

Bamlanivimab is being evaluated together with other antibodies in patients recently diagnosed with mild to moderate COVID-19 to address **emerging variants**.

- **bamlanivimab + etesevimab**
  - Reduces hospitalization & death by 87% in patients recently diagnosed with mild to moderate COVID-19.
  - 99% effective against circulating strains in US
  - Effective against UK strain

- **bamlanivimab + VIR-7831**
  - Currently being evaluated in the BLAZE-4 study for patients recently diagnosed with mild to moderate COVID-19.
  - Predicted to be effective against South African strain
In late January, Eli Lilly moved a next-gen antibody discovered by AbCellera, 1404, into preclinical development. This antibody is:

- Predicted to neutralize all circulating variant strains of COVID-19, including the South African, UK, New York, Brazilian and California variants
- Expected to reach clinical testing in 2021 Q2
- A potential best-in-class therapeutic

Antibody therapies are a complementary approach to vaccines, both now and in the future.
ACQUISITIONS TO EXPAND THE BREADTH & DEPTH OF OUR TECH STACK

2020 BUSINESS UPDATE. TECHNOLOGY EXPANSION

Combine any two antibodies to create bispecific antibodies.

OrthoMab™ bispecific engineering platform, coupled with our discovery engine, has the potential to be best-in-class.

Source fully human antibodies from rodents.

Trianni next-generation mice are suited for generating antibodies against some of the toughest problems in the industry.
THE GOAL: TARGET TO FILL-FINISH IN ONE YEAR.

Future plans for deepening the tech stack include:

- Cell line development
- GMP manufacturing facility for production of biologics for clinical testing

This facility, which is partly funded by a $126M grant by the Government of Canada, will be the first in Canada capable of going from a patient sample to manufacturing antibodies for clinical testing.

AbCellera Receives $126 Million from the Government of Canada to Discover Solutions for COVID-19 and Build a Manufacturing Facility for Antibody Drugs

AbCellera’s world-leading drug discovery technology identifies antibodies for potential use in drugs to treat and prevent COVID-19.
THANK YOU
ABCELLERITES
& OUR FAMILIES
PARTNERSHIP BUSINESS GROWTH CONTINUED AT A RAPID PACE THROUGH 2020

2020 FULL YEAR FINANCIAL RESULTS*

<table>
<thead>
<tr>
<th>Year</th>
<th>+ WITH downstream participation</th>
<th>- WITHOUT downstream participation</th>
<th>5-year CAGR</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>103</td>
<td>22</td>
<td>+28%</td>
</tr>
<tr>
<td>2016</td>
<td>60</td>
<td>27</td>
<td>+56%</td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td>+42%</td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Historical results are not necessarily indicative of future results.
$233.2M Revenue driven by 71% increase in research fees & COVID-19 program

Revenue USD

- Royalties
- Milestones
- Research Fees

2018
- $8.8M

2019
- $11.6M
  - +71%

2020
- $19.8M
  - $15.0M
  - $198.3M
  - Year Total $233.2M

COVID-19 Program Downstream Revenue $213.3M

20X
OPERATING EXPENSES REFLECT CONTINUED STRENGTHENING OF THE PLATFORM & NON-RECURRING COSTS

Operating Expenses USD

<table>
<thead>
<tr>
<th>Category</th>
<th>2019</th>
<th>2020</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research &amp; Development</td>
<td>$10.1M</td>
<td>$29.4M</td>
<td>$19.3M</td>
</tr>
<tr>
<td>Sales &amp; Marketing</td>
<td>$1.3M</td>
<td>$3.8M</td>
<td>$2.5M</td>
</tr>
<tr>
<td>General &amp; Admin</td>
<td>$4.0M</td>
<td>$4.3M</td>
<td>$0.3M</td>
</tr>
<tr>
<td>OrthoMab™</td>
<td></td>
<td>$1.1M</td>
<td></td>
</tr>
<tr>
<td>LCO</td>
<td>$4.3M</td>
<td>$7.3M</td>
<td>$3.0M</td>
</tr>
</tbody>
</table>

Preferred share financing and IPO: $7.3M

Preferred share financing: $1.9M
THREE OTHER PRE-TAX INCOME STATEMENT ITEMS INCREASED BY >$1 MILLION IN 2020

- $2.5M due to amortization of acquired intangible assets over their useful lives
- $4.2M relates to retired OrbiMed credit agreement and previously retired credit facility (non-recurring)
- Mostly Government of Canada SIF project cost recovery

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPRECIATION &amp; AMORTIZATION</td>
<td>$1.6M</td>
<td>$4.8M</td>
</tr>
<tr>
<td>INTEREST &amp; OTHER EXPENSE</td>
<td>$0.2M</td>
<td>$6.5M</td>
</tr>
<tr>
<td>GRANTS &amp; INCENTIVES</td>
<td>$1.8M</td>
<td>$8.3M</td>
</tr>
</tbody>
</table>

+$3.2M

+$6.3M

+$6.5M
EARNINGS JUMPED TO $119M: EQUIVALENT TO $0.53 (BASIC), $0.45 (DILUTED) PER SHARE

**Earnings USD**

- **NET EARNINGS (LOSS)**
  - 2019: ($2.2M)
  - 2020: $118.9M

- **EARNINGS PER SHARE: BASIC**
  - 2019: ($0.01)
  - 2020: $0.53

- **EARNINGS PER SHARE: DILUTED**
  - 2019: ($0.01)
  - 2020: $0.45
SUCCESS IN FINANCING ALLOWED FOR IMPORTANT INVESTMENTS IN 2020 & PROVIDES STRONG LIQUIDITY BEYOND

Cash Flows USD

- $683.7M
- $(90.0M)
- $594.1M

Operations
- $7.6M

Financing
- $22.7M
- $74.7M
- $522.8M
- $(3.8M)
- $90.0M

Investments
- $(119.8M)

Cash & Equivalents
- $522.8M

Additionally, $198.3M accrued AR received subsequent to year end
THANK YOU